Arrowhead announces interim results from AROC3-1001 trial

Arrowhead announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference, or RNAi, therapeutic designed to reduce production of complement component 3, or C3, as a potential therapy for various complement mediated diseases. The company plans to present additional results at an upcoming complement-focused medical meeting. Dosing in Part 2 of the Phase 1/2 study is expected to begin in the first half of 2023. In Part 1 of AROC3-1001, ARO-C3 interim results included: A dose-dependent reduction in serum C3, with 88% mean reduction at highest dose tested; A dose-dependent reduction in AH50, a marker of alternative complement pathway hemolytic activity, with 91% mean reduction at highest dose tested; Duration of pharmacologic effect supportive of quarterly or less frequent subcutaneous dose administration. Overall, no clinically significant laboratory findings or patterns of adverse changes in any clinical laboratory parameters. No dose limiting toxicity, serious or severe adverse events, or study discontinuation due to adverse events. Most common adverse events include headache, COVID-19, generally mild injection site reactions, and seasonal allergy.